Abstract
A drug repurposing approach for Food and Drug Administration (FDA)-approved drugs and preclinical entity by using cheminformatics and chemical transformational method, with the objective of discovering safer novel potent inhibitors that are selective for COVID-19, is reported. We examined the action of lactoferrin against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Lactoferrin was tested not only as therapy but also as a nanocarrier. Among the different repurposed drugs approved to help control the COVID-19 pandemic, we focused on nitazoxanide in a nanodrug delivery form. Lactoferrin activity improved after it was used in combination with nitazoxanide [half-maximal inhibitory concentration (IC50) = 2.72, 1.34 with Selectivity Index (SI) = 25 and 32, respectively]. These results will help us enhance the activity of lactoferrin as a nanocarrier for a variety of selected drugs. In addition, the antiviral activity of the spirooxindole scaffold showed interesting results against SARS-CoV-2 as well as Middle East respiratory syndrome (MERS)-CoV with an IC50 of 0.03 and 0.001 mM, respectively. The molecular modeling study revealed that nitazoxanide has a high similarity to arbidol. Docking outputs emphasize the importance of anilide functionality in drug activity because of its ability to form essential HB main protease and spike protein active sites. By understanding the binding mode, these data will help us design new bioactive drug candidates against SARS-CoV-2.
Article PDF
Avoid common mistakes on your manuscript.
Data availability statement
The authors confirm that the data supporting the findings of this study are available within the article and/or its supplementary materials.
References
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020;5;536–44.
Kupferschmidt K, Cohen J. Will novel virus go pandemic or be contained?. Science 2020;367;610–11.
Mirza MU, Froeyen M. Structural elucidation of SARS-CoV-2 vital proteins: computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 heli-case. J Pharm Anal 2020;10;320–8.
WHO Coronavirus (COVID-19) Dashboard. Available from: https://covid19.who.int/ (accessed February 2, 2021).
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395;497–506.
Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579;265–9.
Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 2005;69;635–64.
Chen B, Liu M, Huang C. Current diagnostic and therapeutic strategies for COVID-19. J Pharm Anal 2021;11;129–137.
Li T, Zhang, T, Gu Y, Li S, Xia N. Current progress and challenges in the design and development of a successful COVID-19 vaccine. Fundam Res 2021;1;139–150.
Batalha PN, Forezi LSM, Lima CGS, Pauli FP, Boechat FCS, de Souza MCBV, et al. Drug repurposing for the treatment of COVID-19: pharmacological aspects and synthetic approaches. Bioorg Chem 2021;106;104488.
Kell DB, Heyden EL, Pretorius E. The biology of lactoferrin, an iron-binding protein that can help defend against viruses and bacteria. Front Immunol 2020;11;1221.
Allam AE, Assaf HK, Hassan HA, Shimizu K, Elshaier YAMM. An in silico perception for newly isolated flavonoids from peach fruit as privileged avenue for a countermeasure outbreak of COVID-19. RSC Adv 2020;10;29983–98.
Kelleni MT Nitazoxanide/azithromycin combination for COVID-19: a suggested new protocol for early management. Pharmacol Res 2020;157;104874.
Mostafa A, Kandeil A, Elshaier YAMM, Kutkat O, Moatasim Y, Rashad AA, et al. FDA-approved drugs with potent in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2. Pharmaceuticals 2020;13;443.
Barakat A, Islam MS, Ghawas HM, Al-Majid AM, El-Senduny FF, Badria FA, et al. Design and synthesis of new substituted spiro-oxindoles as potential inhibitors of the MDM2–p53 interaction. Bioorg Chem 2019;86;598–608.
Barakat A, Islam MS, Al-Majid AM, Ghawas HM, El-Senduny FF, Badria FA, et al. Substituted spirooxindoles. King Saud University, 2017. U.S. Patent 9,822,128. Available from: https://patents.google.com/patent/US9822128B1/en.
Martins JT, Santos SF, Bourbon AI, Pinheiro AC, González-Fernandez A, Pastrana LM, et al. Lactoferrin-based nanoparti-cles as a vehicle for iron in food applications – development and release profile. Food Res Int 2016;90;16–24.
Mofidian R, Barati A, Jahanshahi M, Shahavi MH. Optimization on thermal treatment synthesis of lactoferrin nanoparticles via Taguchi design method. SN Appl Sci 2019;1;1339.
Hamdi M, Abdel-Bar HM, Elmowafy E, Al-Jamal KT, Awad GAS. An integrated vitamin E-coated polymer hybrid nanoplat-form: a lucrative option for an enhanced in vitro macrophage retention for an anti-hepatitis B therapeutic prospect. PLoS One 2020;15;e0227231.
Zhang H, Shi Y, Wang H. Solubility determination of nitazox-anide in twelve organic solvents from T = 273.15 to 313.15 K. J Chem Eng Data 2020;65;3645–51.
Quiñones JP, Brüggemann O, Kjems J, Shahavi MH, Covas CP. Novel brassinosteroid-modified polyethylene glycol micelles for controlled release of agrochemicals. J Agric Food Chem 2018;66;1612–19.
Feoktistova M, Geserick P, Leverkus M. Crystal violet assay for determining viability of cultured cells. Cold Spring Harb Protoc 2016;2016;343–6.
Kandeil A, Mostafa A, El-Shesheny R, Shehata M, Roshdy WH, Ahmed SS, et al. Coding-complete genome sequences of two SARS-CoV-2 isolates from Egypt. Microbiol Resour Announc 2020;9;e00489-20.
Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65;55–63.
Shang L, Nienhaus K, Nienhaus GU. Engineered nanoparticles interacting with cells: size matters. J Nanobiotechnol 2014; 12;5.
Kumar P, Lakshmi YS, Bhaskar C, Golla K, Kondapi AK. Improved safety, bioavailability and pharmacokinetics of zidovudine through lactoferrin nanoparticles during oral administration in rats. PLoS One 2015;10;e0140399.
Duca G, Anghel L, Erhan RV. Structural aspects of lactoferrin and serum transferrin observed by FTIR spectroscopy. Chem J Mold 2018;13;111–16.
Ono K, Sakai H, Tokunaga S, Sharmin T, Aida TM, Mishima K. Encapsulation of lactoferrin for sustained release using particles from gas-saturated solutions. Processes 2021;9;73.
Ali NW, Abbas SS, Zaazaa HES, Abdelrahman MM, Abdelkawy M. Validated stability indicating methods for determination of nitazoxanide in presence of its degradation products. J Pharm Anal 2012;2;105–16.
Sachan AK, Gupta A. Formulation and evaluation of bilayer tablets of nitazoxanide. Der Pharm Lett 2017;9;1–9.
Luo B, Liang H, Zhang S, Qin X, Liu X, Liu W, et al. Novel lactoferrin-conjugated amphiphilic poly(aminoethyl ethylene phosphate)/poly (L-lactide) copolymer nanobubbles for tumor-targeting ultrasonic imaging. Int J Nanomedicine 2015;10;5805-17.
Mahmoud DB, Shitu Z, Mostafa A. Drug repurposing of nitazoxanide: can it be an effective therapy for Covid-19?. J Genet Eng Biotechnol 2020;18;35.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30;269–71.
Elbastawesy MAI, El-Shaier YAMM, Ramadan M, Brown AB, Aly AA, Abuo-Rahma GE-DA. Identification and molecular modeling of new quinolin-2-one thiosemicarbazide scaffold with antimicrobial urease inhibitory activity. Mol Divers 2021;25;13–27.
Rush TS, Grant JA, Mosyak L, Nicholls A. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. J Med Chem 2005;48; 1489–95.
Lee HS, Choi J, Kufareva I, Abagyan R, Filikov A, Yang Y, et al. Optimization of high throughput virtual screening by combining shape-matching and docking methods. J Chem Inf Model 2008;48;489–97.
Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 2020;368;409–12.
Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 2020;582;289–93.
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020;367;1260–3.
Author information
Authors and Affiliations
Corresponding author
Additional information
Peer review under responsibility of the Dr. Sulaiman Al Habib Medical Group
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (https://doi.org/creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Barakat, A., Al-Majid, A.M., Lotfy, G. et al. Drug Repurposing of Lactoferrin Combination in a Nanodrug Delivery System to Combat Severe Acute Respiratory Syndrome Coronavirus-2 Infection. Dr. Sulaiman Al Habib Med J 3, 104–112 (2021). https://doi.org/10.2991/dsahmj.k.210810.001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/dsahmj.k.210810.001